Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets for the use as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, hydromorphone HCl, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has collaboration and license agreements with Egalet US, Inc.; Egalet Ltd.; and Egalet Corporation to manufacture and commercialize Oxaydo products worldwide. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.